Table 1. Adoptive transfer of CpG-proB cells but not of control pro-B cells inhibits ongoing EAE.

Group	Mice	Mean maximum score±s.e.m.	Day of onset±s.e.m.	Disease incidence
Control	30	3.51±0.89	13.56±1.40	100%
WT CpG-proBs	30	1.56±1.26**	14.50±2.22	76.7%*
Control ProBs	20	3.57±0.92	13.30±2.22	100%
PBS-proBs	4	3.50±0.05	12.00±0.00	100%

Clinical parameters from data in Fig. 1e, including the maximum clinical score (mean±s.e.m.) of each treatment group and the day of disease onset (mean±s.e.m.) among mice with EAE as well as the disease incidence over the entire observation period (35 days). Control mice received PBS injection instead of progenitor injection. Significant differences between CpG-proB recipients versus control mice are indicated; *P<0.05, **P<0.005, assessed by non-parametric Mann–Whitney's t-test.